在HFpEF中的糖代谢性心脏功能障碍:多omics研究的教训.
Susanna Longo1, Rocco Mollace2, Viviana Casagrande3
1Department of Systems Medicine and Center for Atherosclerosis, University of Rome Tor Vergata and Policlinico Tor Vergata, Rome 00133, Italy; Nutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IDIBGI-CERCA), Girona, Spain.
Pharmacological research
|November 14, 2025
概括
心脏衰竭与保存的排泄分数 (HFpEF) 涉及到心脏组织的代谢变化. 多组学和人工智能可以发现个性化HFpEF治疗和更好的患者分层的新生物标志物.
科学领域:
- 心血管医学 心血管医学
- 生物化学 生物化学
- 基因组学和蛋白质组学
背景情况:
- 保存排泄分数的心脏衰竭 (HFpEF) 是一种复杂的综合征,其特征是心肌生化变化.
- 心脏组织中代谢灵活性的丧失是HFpEF病原和进展的潜在贡献者.
- HFpEF的异质性使研究和临床管理复杂化,需要对其病理生理学和表型有更深入的了解.
研究的目的:
- 探索心肌代谢变化和不灵活性在HFpEF发展中的作用.
- 通过使用多omics方法来识别HFpEF的潜在omics签名.
- 通过启用新的生物标志物来诊断,表型,风险分层和向治疗来推进个性化医疗.
主要方法:
- 对HFpEF中心肌代谢变化的当前文献的综述.
- 分析多学科研究的见解,包括人工智能和机器学习应用.
- 专注于识别超出临床和人口统计数据的非传统生物标志物.
主要成果:
- 心肌的代谢不灵活性与HFpEF病变发生有关.
- 多omics方法为发现以前无法获得的关于HFpEF代谢变化和表型的见解提供了潜在的潜力.
- 识别omics签名可能有助于发现新的生物标志物.
结论:
- 了解心肌代谢变化对于破译HFpEF病理生理学至关重要.
- 多组学和人工智能对表征HFpEF表型和识别新生物标志物具有重大前景.
- 这种方法可以推动个性化治疗的发展,并改善HFpEF患者的治疗结果.
相关概念视频
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
01:29Heart Failure II: Pathophysiology
695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695
01:29Pathophysiology of Cardiac Performance
1.3K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.3K
01:27Heart Failure I: Introduction
671
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
671
01:30Cardiomyopathy II: Dilated Cardiomyopathy
451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451